AiCuris Announces that its Licensee MSD Received Positive CHMP Opinion for PREVYMIS™ (Letermovir) Recommending Approval in Europe
Wuppertal, Germany, November 13, 2017- AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA), received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of PREVYMIS (letermovir) for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT) in Europe.
Full PR available here